Price:
Rs. 21,000.00
Sample Type: EDTA Blood
Fasting Not Required
Notes:N8277
Frequently Asked Questions (FAQ's):
What does the NextGen B-ALL Risk Stratification Panel include?
It assesses multiple leukemia-associated genes to detect mutations that impact prognosis, treatment response, and disease aggressiveness.
Why is this test important?
It helps determine patient-specific risk levels, enabling oncologists to choose optimal treatment intensity and targeted therapies.
Who should take this test?
Patients diagnosed with B-cell Acute Lymphoblastic Leukemia who are beginning treatment, undergoing reassessment, or experiencing relapse may need this panel.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare utilizes high-depth Next Generation Sequencing to identify single nucleotide variants, indels, and other relevant mutations.
What sample is required?
A blood sample collected in an EDTA vial is needed for genetic analysis.
Is any special preparation required?
No special preparation or fasting is needed before sample collection.
How fast are the results available?
Metropolis Healthcare provides a detailed genomic report within a clinically appropriate timeframe to guide timely decisions.
Can this test guide treatment strategies?
Yes, the results help tailor chemotherapy, immunotherapy, and targeted therapy approaches based on individual genetic risk factors